Cargando…
The Off-Patent Biological Market in Belgium: Is the Health System Creating a Hurdle to Fair Market Competition?
We investigated the off-patent biological market in Belgium from a policy maker’s perspective, in light of the Belgian pharmaceutical health system. The main barriers relate to a short-term budgetary focus, to the overwhelming innovator’s reach and to a concertation model with assessment and apprais...
Autor principal: | Wilder, Philippe Van |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069942/ https://www.ncbi.nlm.nih.gov/pubmed/33920150 http://dx.doi.org/10.3390/ph14040352 |
Ejemplares similares
-
Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
por: Vandenplas, Yannick, et al.
Publicado: (2021) -
Dynamics of price competition in Italian pharmaceutical off-patent market
por: Perna, Serena, et al.
Publicado: (2022) -
Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study
por: Vandenplas, Yannick, et al.
Publicado: (2022) -
An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
por: Moorkens, Evelien, et al.
Publicado: (2020) -
Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
por: Barcina Lacosta, Teresa, et al.
Publicado: (2022)